Roche Holding Ltd (RHHBY): "Bavituximab" ... its MOA is being tried...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	86
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: Princessbarbie post# 97

Saturday, 06/08/2013 12:30:54 PM

Saturday, June 08, 2013 12:30:54 PM

"Bavituximab" ... its MOA is being tried by others by Peregrine has the patent locked up for the upper up stream target of Phosphatidylserine (PS). No other Big Pharma can target it... and when you target PS which is outside the cell cembrane, the result is less side affects. No toxic side affects.

Peregrine just went to ASCO 2013 with a Phase III pre-approval for their NSCLC phase IIb trial so we know where the FDA stands if they approved this before ASCO 2013. Peregrine/Genetech/Roche... wow, just imagine that : ) If Avastin has the side affects and replaced by Bavi... Avastin/Roche will be more like it.

GLTA!

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!